 |
|
 |
|
|
|
|
 |
 |
 |
|
AXCS is a site-directed drug targeting company using bioresponsive carriers to target and control the release of therapeutic agents into sites of disease activity and significantly improve the side effect profile of the agents. The Company has proprietary rights to four technology platforms: synthetic polymers, Residerm®, carbohydrate targeting technology and selective muscle and nerve delivery systems. AXCS' first FDA approved product, Aphthasol(tm), a 5% amlexanox paste, is the only prescription drug approved in the US for the treatment of aphthous ulcers, or canker sores, in people with normal immune systems. AXCS is actively seeking international distribution partners in Europe and the Far East. AXCS is also developing polymer platinate for use in cancer treatment where platinum compounds are currently indicated. AXCS proprietary polymer delivery system provides for better site targeting of the platinum compound, resulting in greater amounts of platinum being delivered to the tumor over a longer period of time. The Residerm platform technology will be used to improve the efficacy of a number of topically delivered compounds, including acne treatments, steroids, vitamin D, retanoids and anti-fungals.
SMALLCAPS RESEARCH
- Virologix Acquisition Announced; Reiterate BUY (03/03/99)
- Amlexanox Right Acquired; Reiterate BUY (01/12/99)
- Initial Opinion (10/27/98)
- Financial Model